Yargı: Anahtar Kelimeler: INTRODUCTION MATERIAL AND METHODS Participants

Size: px
Start display at page:

Download "Yargı: Anahtar Kelimeler: INTRODUCTION MATERIAL AND METHODS Participants"

Transcription

1 Journal of Neurological Sciences [Turkish] 32:(1)# 43; , Research Article Combination Treatment of Atorvastatin and Fasudil Ameliorate Cerebral Vasospasm after Subarachnoid Hemorrhage Renguo LUO, Jie FAN, Jie DUAN, Lin FENG, Xiaohong YIN Department of Neurosurgery Affiliated Hospital North Sichuan Medical College Sichuan Nanchong, China Summary Objective: Cerebral vasospasm (CV) and early brain injury remain major causes of morbidity and mortality after aneurysmal subarachnoid hemorrhage (SAH). The aims of this study were to investigate whether combination treatment, with atorvastatin as an inhibitor of RhoA and fasudil as an inhibitor of Rho-kinase, prevents the CV. Methods: Atovastatin, fasudil, or combination treatment were administrated. Ischemic lesion size was measured using computed tomography on the last available scan. Angiographic narrowing was semiquantitatively assessed in patients with vasospasm. The primary end point was the occurrence of cerebral infarction or symptomatic vasospasm (SV) caused by CV. The secondary end point was clinical outcome 6 months later. Results: In the trial population, cerebral infarction(20.5% vs.27.5% vs.29.3%) and SV(20.5% vs.26.8% vs. 27.5%) were significantly lower in the combination treatment group than in fasudil and atovastatin groups (both P<0.05). No differences were found between statin, fasudil, and combination groups regarding rescue therapy intensity (P>0.05), mrs (P=0.06), and GOS (P>0.05) at 6 months. In the overall population, patients with SV had poorer clinical outcomes (P=0.05). Conclusion: Combination treatment reduces the incidence, severity and the ischemic consequences of vasospasm. Although no improvement of clinical outcome was seen in the combination population, there was a tendency for a better clinical outcome. Key words: Atorvastatin; Fasudil; Cerebral Vasospasm; Subarachnoid Hemorrhage Subaraknoid Kanama Sonrası Serebral Vazospazmı Atorvastatin ve Fasudil Kombine Tedavisi Düzeltir Özet Giriş: Anevrizmal subaraknoid kanama (SAH) sonrası gelişen serebral vazospazm (CV) ve erken beyin yaralanması morbidite ve mortalitenin ana nedenleri arasındadır. Bu çalışmanın amacı bir RHoA inhibitörü olan atorvastatin ile bir Rho-kinaz inhibitörü olan fasudilin birlikte kullanılmasının CV yi önleyip önleyemeyeceğini araştırmaktır. Yöntemler: Atovastatin, fasudil, ya da kombinasyonu tedavi olarak verildi. İskemik lezyon alanı en son olası BT tetkikinde ölçüldü. Anjigrafik daralma yarıkantitatif olarak vazospazmlı hastalarda değerlendirildi. Primer son nokta nedeni CV olan serebral infarktın varlığı ya da semptomatik vasospazmın (SV) görülmesi oldu. İkincil varış noktası ise 6 ay sonraki klinik sonuç idi. Sonuçlar: Deneme örneğinde serebral infarkt (20,5% vs.27,5% vs.29,3%) ve SV(20,5% vs.26,8% vs. 27,5%) tekli fasudil ve atorvastatin tedavi gruplarına göre kombine tedavi grubunda önemli ölçüde daha düşük bulundu. (her iki P<0,05). Statin, fasudil ve kombinasyon gruplarında kurtarma tedavisi yoğunluğu (p>0,05), mrs (p=0,06) ve GOS (p>0,05) bazında 6 40

2 ay sonrasında bir farklılık bulunmadı. Tüm denek örneğinde SV hastaları en kötü klinik sonuçları gösterdi (P=0,05). Yargı: Kombinasyon tedavisi vazospazmım iskemik sonuçlarını, görülme sıklığını ve şiddetini azaltmaktadır. Klinik sonuç olarak herhangi bir iyileştirme sonucu olamamakla birlikte daha iyi bir klinik sonuç oluşturma eğilimi vardır. Anahtar Kelimeler: Atorvastatin; Fasudil; Serebral Vazospazm; Subaraknoid Kanama INTRODUCTION Aneurysmal subarachnoid hemorrhage (SAH) is a major cause of stroke, as approximately 15% stroke cases are due to ruptured intracranial aneurysms. (7) Outcome after SAH depends on several factors, including the severity of the initial event, the peri-ictal medical management, various surgical variables, and the incidence of SAH induced complications. Cerebral vasospasm (CV) is the most frequent and unpredictable complication after SAH and leads to adverse outcomes. (15) The development of vasospasm is related to a number of pathological processes, including endothelial damage, smooth muscle cell contraction, and inflammatory reactions. (31) Recent studies suggested that Rho/Rho kinase pathway is an important target in the pathogenesis of various vascular diseases. (13,33) The G protein-coupled receptor is activated by clot-derived substances that alter the subarachnoid space after SAH and that induce the activation of RhoA followed by activation of Rho-kinase. (30) Fasudil, the Rho-kinase inhibitor, protects neurons, improves neurological function, inhibits ischemic cerebral injuries (24), and prevents and reverses CV. (37) Some study (12,20) indicate that fasudil significantly improves the clinical outcome in SAH patients by preventing and reversing CV. However, the other studies (16,38) do not support this finding. Statins, inhibitors of the 3-hydroxy-3- methylglutarylcoenzyme A (HMG-CoA) reductase, are widely used as cholesterollowering drugs. Studies have shown that high concentrations of statins enhance endothelial function (11), and protect against stroke, (10) by mechanisms involving inhibition of RhoA. (35) These so-called pleiotropic effects of statins are thought to be responsible for the observed improvement in flow-mediated vasodilation, (9) increased numbers of circulating endothelial progenitor cells, (9) and perhaps the reduction in vascular inflammation. (22) However, the full effects of the statins on cerebral vasospasm after SAH remain controversial. (14) Although neither fasudil nor statin show remarkable effects in preventing cerebral vasospasm after SAH, a combination use of these drugs might effectively suppress the Rho-kinase pathway. Therefore, in this prospective, randomized, efficacy study, atorvastatin and fasudil were used to examine whether combination therapy prevent CV and improve clinical outcomes after SAH onset. MATERIAL AND METHODS Participants A total of 128 patients were enrolled at our department between April 2010 to April All patients underwent SAH surgery and randomly assigned (1:1:1) to atorvastatin group, fasudil group, and combination group with atorvastatin and fasudil. Patients in all groups were admitted to the stroke intensive care unit. Treatment after surgery included intracranial pressure control and cisternal drainage. A computer-generated randomisation code was used to randomise patients. Inclusion criteria were radiological confirmatory evidence of an aneurysmal subarachnoid haemorrhage (by CT angiography (CTA), magnetic resonance angiography (MRA), or digital 41

3 subtraction angiography (DSA), age years, presentation less than 72h from ictus, and first surgery patients. Exclusion criteria were patient taking statin therapy at presentation, pregnancy or of child-bearing potential, no reasonable prospect of survival, known renal or hepatic impairment, patient not fully independent before bleed, strong suspicion of drug or alcohol misuse, patient taking contraindicated medication (amiodarone, amlodipine, verapamil, or potent CYP3A4 inhibitors), patient taking warfarin-type drugs, metabolic disease(such as diabetes), or suspected additional life-threatening disease. We obtained ethics approval from the Ethics Committee of our hospital. Informed written consent from were obtained from all patients or their legal representative. Procedures Patients started treatment as soon as possible within 72 h of the ictus, for a period of up to 3 weeks. Patients were randomized to the atorvastatin (LIPITOR, Pfizer, USA), fasudil (ERIL Injection, Asahi Kasei Corporation, Japan), and combination therapy group, and treatment with atorvastatin, fasudil, or combination therapy was started within 24 hours after aneurysm surgery and continued for 21 consecutive days. Fasudil 30mg was prescribed for intravenous administration three times a day. Atorvastatin was administrated 20mg a day. The drugs were stopped when patients were discharge, and continuation of trial medication thereafter was deemed unnecessary. Commencement of study drug was not dependent on aneurysm treatment. Outcomes The patients were followed daily for one month after SAH. The primary outcome was cerebral infarction or symptomatic vasospasm (SV) caused by CV. Secondary outcomes were the assessment of delayed ischaemic deficit requiring rescue therapy, modified Rankin Scale (mrs) scores, and Glasgow Outcome Scale(GOS) at 6 months. CV was defined as a newly detected, low-density area identified by CT when all other causes of formation of low density areas, for instance, low-density areas around the hematoma, were excluded. (27) We defined SV as a documented arterial vasospasm consistent with new neurologic deterioration, either transient or permanent, occurring on days 4 to 30 after SAH onset. (27) CT was performed whenever clinical deterioration was noted. The presence of arterial vasospasms was diagnosed by mean arterial velocities >120 cm/s in the middle or anterior cerebral arteries or >90 cm/s in the basilar arteries measured using transcranial Doppler ultrasonography. (21) Patients with these findings typically underwent CT angiography to confirm the presence of vasospasms. (28) We confined reporting of adverse events in this study to serious adverse events and those that we deemed to be related to trial medication. Statistical analysis Statistical analyses were performed using Statistical Analysis Software versions 8.2 and 9.1 (SAS Institute Inc., Cary, North Carolina, USA). Characteristics at baseline were compared using the Wilcoxon rank sum test. An X 2 test was used to compare class variables. The inhibitory effects of statin and fasudil on cerebral infarction and SV were evaluated by multivariate logistic regression analysis. The significance level was set at P < RESULTS Clinical and Demographic Data The clinical and demographic data of the 120 remaining patients are shown in Table 1. There were no significant differences in age, sex, aneurysm location, Fisher classification of CT findings, mean time from onset of SAH to treatment, and treatment modality between the three groups(all P>0.05). Severe SAH (WFNS grades IV and V) was present in 9 patients in the combination group, 8 in atorvastatin group and 9 in fasudil group, and the 42

4 WFNS grades did not differ significantly between the 3 groups( P>0.05). Cerebral infarction and SV The frequency of cerebral infarction and SV was evaluated in all patients. The incidence of cerebral infarction caused by CV occurred in 8/39 patients (20.5%) in combination group, 11/40 (27.5%) in fasudil group, and 12/41 (29.3%) in atorvastatin group, which is significantly lower in the combination treatment group than in the other two groups (20.5% vs. 27.5% vs. 29.3%, P< 0.05). Fewer patients had cerebral infarction in the combination group than in the atorvastatin or fasudil group (10.3 vs. 19.5% vs.17.5%, P<0.05). Multivariate analysis revealed an adjusted odds ratio of 0.37 (95% confidence interval , P=0.33) for cerebral infarction by combination treatment. The frequency of SV in all 120 patients also was significantly lower in the combination group than in atorvastatin or fasudil group (20.5% vs. 26.8% vs. 27.5%, P=0.048; Table 2). Multivariate analysis revealed an adjusted odds ratio of 0.46 (95% confidence interval , P=0.044) for SV inhibition by combination treatment. Clinical Outcomes Use of extended hypervolaemic therapy differed between 3 groups (P= 0.03) (Table 3), although the duration of extended hypervolaemic therapy was the same (8 days in all 3 groups). The need for hypertensive inotropic, angioplasty, and steroids support showed no differences between 3 groups (all P>0.53). Clinical outcomes were assessed using the mrs. The percentages of patients with a favorable outcome (mrs=0-2) did not differ significantly between the three groups (63.4% vs. 67.5% vs. 69.2%, P= 0.33) on 6 months after SAH onset (Table 3). The effect of the occurrence of SV on the clinical outcome also was examined. Fewer patients with SV had a favorable outcome compared with those without SV on 6 months (60% vs. 70%, P = 0.05) after the onset of SAH (Table 4). The occurrence of SV did not affect the outcomes in patients in the combination group on 6 months after SAH onset, but patients in the atorvastatin and fasudil group with SV had significantly poorer outcomes on 6 months (Table 4). Adverse events were observed in 6/39(15.4%) patients in the combination group, in 5/40(12.5%) in fasudil group and in 6/42(14.3%) in atorvastatin group, with no significant difference between the three groups (P>0.05). Table 1 Basic clinical and demographic characteristic of patients Atorvastatin Fasudil group Combination group group Age, years 51±6.2 50±5.9 52±6.3 Male sex n(%) 23(56.1) 22(55.0) 24(61.5) WFNS SAH grade n(%) I 18(43.9) 17(42.5) 16(41.0) II 8(19.5) 8(20.0) 7(17.9) III 7(17.1) 6(15.0) 7(17.9) IV 3(7.3) 5(12.5) 4(10.2) V 5(12.2) 4(10.0) 5(12.8) Fisher grade n (%) 1 5(12.2) 4(10.0) 6(15.4) 2 8(19.5) 8(20.0) 7(17.9) 3 12(29.3) 13(32.5) 11(28.2) 4 16(39.0) 15(37.5) 15(38.5) Location of aneurysm n (%) 43

5 30.8Anterior 12(29.3) 11(27.5) 12(30.8) communicating Posterior 9(22.0) 8(20.0) 8(20.5) communicating Internal carotid 4(9.8) 4(10.0) 4(10.3) Middle cerebral 8(19.5) 9(22.5) 7(17.9) Posterior circulation 4(9.8) 4(10.0) 5(12.8) Other 3(7.3) 4(10.0) 3(7.7) Mean time from onset of 2.1± ± ±0.4 SAH to treatment, days Treatment modality n(%) Clipping 13(31.7) 12(30.0) 11(28.2) Coiling 23(56.1) 24(60.0) 24(61.5) Clipping+ coiling 3(7.3) 2(5.0) 3(7.7) Other 2(4.9) 2(5.0) 1(2.6) Table 2 Incidence of Cerebral infarction and Symptomatic vasospasm Atovastatin Fasudil Combination P value Odds ratio P value group(n=41) group(n=40) group(n=39) (X 2 test) (95%CI) Cerebral infarction n (%) 8/41(19.5) 7/40(17.5) 4/39(10.3) ( ) Symptomatic vasospasm n (%) 11/41(26.8) 11/40(27.5) 8/39(20.5) ( ) Atorvastatin group(n=41) Table 3 Clinical outcome measures Fasudil group (n=40) Combination group(n=39) P value Rescue therapy n (%) Extended 10(24.4) 9(22.5) 5(12.8) 0.03 hypervolaemic therapy Inotropic support 8 (19.5) 9 (22.5) 8 (12.3) 0.55 Angioplasty 3 (7.3) 4(10.0) 3 (7.7) 0.46 Steroids 7 (17.1) 8 (20.0) 7 (17.9) 0.67 mrs at 6 months n (%) 26 (63.4) 27 (67.5) 28 (71.2) 3-4 n (%) 11 (26.8) 10 (25.9) 8 (20.5) 5-6 n (%) 5 (12.2) 5 (12.5) 3 (7.8) GOS at 6 months n (%) 8 (19.5) 9 (22.5) 6 (15.4) 4 n (%) 4 (9.8) 4 (10.0) 3 (7.7) 5 n (%) 29 (70.1) 29 (72.5) 30 (76.9) 44

6 Table 4 Favorable Clinical outcomes in patients with or without SV on six months after the onset of SAH With SV Without SV P value Total patients 18/30 (60.0) 63/90 (70.0) 0.05 Atorvastatin group 6/11 (54.5) 20/30 (66.7) 0.04 Fasudil group 6/11 (54.5) 21/29 (72.4) 0.02 Combination group 6/8 (75.0) 22/31 (71.0) 0.35 Note: Scores of 0-2 on the mrs were considered to be favorable outcomes. DISCUSSION In our study, combination treatment significantly reduced vasospasm incidence, vasospasm severity, and vasospasminduced brain ischemia as assessed by CT. The results of this randomized study confirm that combination treatment of atorvastatin and fasudil significantly inhibits CV and SV after SAH onset. The present study also shows that combination treatment affords benefit tendency in clinical outcomes after acute aneurysmal SAH, comparing to atorvastatin or fasudil treatment. The Rho/Rho-kinase pathway has been considered as playing an important role in sustained contraction during cerebral vasospasm after aneurysmal SAH. (26) After SAH, it is thought that the Rho/Rho-kinase pathway is activated (5) by many cytokines. Rho-kinase activates MLC kinase resulting (39) in sustained contraction of smooth muscle cells. Inhibition of the Rho/Rho-kinase pathway is therefore considered to represent potential therapy preventing cerebral vasospasm. Fasudil is a selective inhibitor of Rho-kinase, mediating an increase in the myocardial NO content. (36) In addition, fasudil is indicated to have pleiotropic effects for cerebral vasospasm, such as protection from endothelial cell damage and antiinflammatory effects. (17) Several clinical studies have shown that fasudil suppresses cerebral vasospasm and the associated cerebral ischemic symptoms; however, it has also been demonstrated as failing to show sufficient effect in terms of preventing cerebral vasospasm as single use. (29) On the other hand, statins were isolated about 40 years ago as a molecules could inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, reducing serum cholesterol concentrations. (24) Statins that decreased serum cholesterol and reduced heart disease and stroke were identified. (1) In addition to the reduction of cholesterol synthesis, decreased synthesis of farnesylpyrophosphate and geranylgeranylpyrophosphate might also occur. These compounds bind to proteins such as heterotrimeric G proteins (Ras, Rho, and others) in a process called protein prenylation. (2,3) RhoA was shown to be inhibited by statin. (23) Thus, statins might affect many cellular signal transduction pathways. In experimental studies, statin was shown to ameliorate cerebral vasospasm, improve cerebral autoregulation, and reduce vasospasmrelated injury, by upregulating enos. (18) But, effects of statins on cerebral vasospasm and neurological outcome after SAH were still controversial. (5,8) Therefore, we speculated that a combination treatment of statin, for RhoA and enos, and fasudil, for Rho-kinase, might suppress the Rho/Rho-kinase pathway more intensely than the single use of statin or fasudil alone. In animal study, results indicate that combination treatment could extensively prevent cerebral vasospasm due to the synergic effect of combining pitavastatin and fasudil on the Rho/Rho-kinase pathway and on enos. (19) The decreased activity of Rho-kinase induced by fasudil 45

7 may play a role as a feedback to reduce RhoA activity. (32) On the other hand, the combination group showed a statistically significant improvement in clinical outcome after acute aneurysmal SAH, suggesting that a combination of statin and fasudil could achieve a synergic effect. Its reduction in activity by statin may be increased by the depression of RhoA activity, and its reduction in activity by fasudil may due to the direct effect of fasudil on Rho-kinase. Study showed a reduction of enos expression in the endothelial cells after SAH. The enos expression was enhanced in the combination group and the statin group, but its expression was not enhanced in the fasudil group. (38) Therefore, despite the incomplete effects of statin or fasudil alone in the prevention of cerebral vasospasm, a combination treatment can achieve adequate effects in this clinical study. In our study, the combination treatment can greatly induce remarkable amelioration of cerebral vasospasm, which may suggest the Rho/Rho-kinase pathway was one of the main pathways inducing sustained contraction of smooth muscle cells during cerebral vasospasm. Although the combination treatment reduced the development of SV and cerebral infarction in this study, we also found that clinical outcomes in patients in the combination and control groups were not different. Study suggests that cerebral infarction after SAH contributes to poor outcome. (4) A placebo group was not included due to the ethical implications of withdrawing antispasmodic therapy in patients with SAH in this study. The incidences of cerebral vasospasm in fasudil and statin groups are low (17.5% and 19.5%, respectively), comparing with the incidences of 38%-44% in the control groups in previous studies. (27,34) All three groups were administrated of antispasmodic drugs to prevent further worsening of outcomes when SV occurred in each group. Therefore, the clinical outcomes in patients in the fasudil or statin group in this study were so favorable that no significant differences were detected between the three groups. We only found a benefit tendency in clinical outcomes after combination treatment (mrs comparison, p=0.06) We also found that patients without SV had more favorable outcomes compared with patients with SV, and clinical outcomes in the combination treatment group were affected by the development of SV (Table 4). Furthermore, among patients with SV, those in the combination group had more favorable outcomes than those in the fasudil or statin group, which may suggest that combination treatment inhibits the development of SV after SAH and also prevents worsening of SV through cerebral vasospasm inhibition and multiple pleiotropic effects. In conclusion, the results of this study show that combination treatment inhibits the development of SV and CV after SAH onset. The may be due to inhibition of the Rho-kinase pathway, enhancement of enos expression, neuroprotective and multiple pleiotropic effects. We also showed that combination treatment can be safely used to prevent vasospasm after the onset of SAH with no significant adverse effects. Further well-designed controlled trials involving a larger number of patients are required to confirm the effect of atorvastatin and fasudil combination treatment on the clinical outcomes of patients with SAH. Correspondence to: Xiaohong Yin liuban@126.com Received by: 19 June 2014 Revised by: 05 January 2015 Accepted: 05 January

8 The Online Journal of Neurological Sciences (Turkish) This e-journal is run by Ege University Faculty of Medicine, Dept. of Neurological Surgery, Bornova, Izmir-35100TR as part of the Ege Neurological Surgery World Wide Web service. Comments and feedback: URL: Journal of Neurological Sciences (Turkish) Abbr: J. Neurol. Sci.[Turk] ISSNe REFERENCES 1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: Eisa-Beygi S, Hatch G, Noble S, et al. The 3- hydroxy-3-methylglutaryl-coa reductase (HMGCR) pathway regulates developmental cerebral-vascular stability via prenylationdependent signalling pathway. Dev Biol 2013; 373: Flaster M, Morales-Vidal S, Schneck MJ, et al. Statins in hemorrhagic stroke. Expert Rev Neurother 2011; 11: Kassell NF, Sasaki T, Colohan AR, et al. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 1985; 16: Kirkpatrick PJ, Turner CL, Smith C, et al. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol 2014; published online May / S (14) Kozasa T, Hajicek N, Chow CR, et al. Signalling mechanisms of Rho GTPase regulation by the heterotrimeric G proteins G12 and G13. J Biochem. 2011; 150(4): Kramer A, Fletcher J. Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage?: a meta-analysis. Stroke 2009; 40: Kramer AH, Gurka MJ, Nathan B, et al. Statin use was not associated with less vasospasm or improved outcome after subarachnoid hemorrhage. Neurosurgery 2008; 62: Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: Laufs U, Endres M, Stagliano N, et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 2000; 106: Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: Li CH, Ye JY, Du P, et al. Effective evaluation of combined treatment in delayed cerebrovascular spasm after subarachnoid hemorrhage. J Apoplexy Nerv Dis 2009; 26: Lohn M, Plettenburg O, Ivashchenko Y, et al. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 2009; 54: Macdonald RL. Are statins to be STASHed in subarachnoid haemorrhage? Lancet Neurol. Lancet Neurol 2014; 13 (7): Macdonald RL, Higashida RT, Keller E, et al. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocrit Care 2010; 13: Ma JJ, Yang SY, Wei W, et al. A phase clinical evaluation of fasudil hydrochloride for cerebral vasospasm following subarachnoid hemorrhage. Chin J Neurosurg 2006; 22: Ma Z, Zhang J, Du R, et al. Rho kinase inhibition by fasudil has anti-inflammatory effects in hypercholesterolemic rats. Biol Pharm Bull 2011; 34 (11): McGirt MJ, Lynch JR, Parra A, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke J Cereb Circ 2002; 33(12): Naraoka M, Munakata A, Matsuda N, et al. Suppression of the Rho/Rho-kinase pathway and prevention of cerebral vasospasm by combination treatment with statin and fasudil after subarachnoid hemorrhage in rabbit. Transl Stroke Res 2013; 4 (3): Nakashima S, Tabuchi K, Shimokawa S, et al. Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 1998; 38: Rabinstein AA, Pichelmann MA, Friedman JA, et al. Symptomatic vasospasm and outcomes following aneurysmal subarachnoid hemorrhage: a comparison between surgical repair and endovascular coil occlusion. J Neurosurg 2003; 98: Ridker PM, Cannon CP, Morrow D, et al. Creactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: Rattan S. 3-Hydroxymethyl coenzyme A reductase inhibition attenuates spontaneous smooth muscle tone via RhoA/ROCK pathway regulated by RhoA prenylation. Am J Physiol Gastrointest Liver Physiol 2010; 298 (6): G

9 24. Sabri M, Macdonald RL. Statins: a potential therapeutic addition to treatment for aneurysmal subarachnoid hemorrhage? World Neurosurg 2010; 73: Satoh S, Hitomi A, Ikegaki I, et al. Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. Brain Res Bull 2010; 81: Sato M, Tani E, Fujikawa H, et al. Involvement of Rhokinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res. 2000; 87 (3): Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992; 76: Shirao S, Yoneda H, Ishihara H, et al. Survey Study Members of Japan Neurosurgical Society: A proposed definition of symptomatic vasospasm based on treatment of cerebral vasospasm after subarachnoid hemorrhage in Japan: Consensus 2009, a project of the 25 Spasm Symposium. Surg Neurol Int 2011; 2: Suzuki Y, Shibuya M, Satoh S, et al. Safety and efficacy of fasudil monotherapy and fasudilozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir 2008; 48(6): Takai Y, Sasaki T, Tanaka K, et al. Rho as a regulator of the cytoskeleton. Trends Biochem Sci 1995; 20(6): Takizawa T, Tada T, Kitazawa K, et al. Inflammation cytokine cascade released by leukocytes in cerebrospinal fluid after subarachnoid hemorrhage. Neurol Res 2001, 23: Tang AT, Campbell WB, Nithipatikom K. ROCK1 feedback regulation of the upstream small GTPase RhoA. Cell Signal 2012; 24(7): Tiftik RN, Erol A, Cnar MG, et al. Nitric oxide does not down regulate Rhokinase (ROCK-2) expression in rat coronary endothelial cells. J Cardiovasc Pharmacol 2008; 51: Vajkoczy P, Meyer B, Weidauer S, et al. lazosentan (AXV ), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebocontrolled, multicenter phase IIa study. J Neurosurg 2005; 103: Wang HW, Liu PY, Oyama N, et al. Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR / mice. FASEB J 2008; 22: Wu N, Li W, Shu W, et al. Inhibition of Rhokinase by fasudil restores the cardioprotection of ischemic postconditioninng in hypercholesterolemic rat heart. Mol Med Rep 2014; 10 (5): Yamaguchi S, Tanabe K, Takai S, et al. Involvement of Rho-kinase in tumor necrosis factor-alpha-induced interleukin-6 release from C6 glioma cells. Neurochem Int 2009; 55: Zhao JZ, Zhou DB, Guo J, et al. Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 2006; 46: Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011; 32(3):

7/18/2018. Cerebral Vasospasm: Current and Emerging Therapies. Disclosures. Objectives

7/18/2018. Cerebral Vasospasm: Current and Emerging Therapies. Disclosures. Objectives Cerebral : Current and Emerging Therapies Chad W. Washington MS, MD, MPHS Assistant Professor Department of Neurosurgery Disclosures None Objectives Brief Overview How we got here Review of Trials Meta-analysis

More information

THE EFFICACY AND SAFETY OF CILOSTAZOL IN SUBARACHNOID HEMORRHAGE. A META- ANALYSIS OF RANDOMIZED AND NON RANDOMIZED STUDIES DR. MUHAMMAD F.

THE EFFICACY AND SAFETY OF CILOSTAZOL IN SUBARACHNOID HEMORRHAGE. A META- ANALYSIS OF RANDOMIZED AND NON RANDOMIZED STUDIES DR. MUHAMMAD F. THE EFFICACY AND SAFETY OF CILOSTAZOL IN SUBARACHNOID HEMORRHAGE. A META- ANALYSIS OF RANDOMIZED AND NON RANDOMIZED STUDIES DR. MUHAMMAD F. ISHFAQ ZEENAT QURESHI STROKE INSTITUTE AND UNIVERSITY OF TENNESSEE,

More information

Age-Associated Vasospasm in Aneurysmal Subarachnoid Hemorrhage

Age-Associated Vasospasm in Aneurysmal Subarachnoid Hemorrhage Age-Associated Vasospasm in Aneurysmal Subarachnoid Hemorrhage Sushant P. Kale, MD, MPH,* Randall C. Edgell, MD,* Amer Alshekhlee, MD,* Afshin Borhani Haghighi, MD,* Justin Sweeny, MD, Jason Felton, MD,

More information

Epidemiology And Treatment Of Cerebral Aneurysms At An Australian Tertiary Level Hospital

Epidemiology And Treatment Of Cerebral Aneurysms At An Australian Tertiary Level Hospital ISPUB.COM The Internet Journal of Neurosurgery Volume 9 Number 2 Epidemiology And Treatment Of Cerebral Aneurysms At An Australian Tertiary Level Hospital A Granger, R Laherty Citation A Granger, R Laherty.

More information

(aneurysmal subarachnoid hemorrhage, 17%~60% :SAH. ,asah , 22%~49% : Willis. :1927 Moniz ;(3) 2. ischemic neurological deficit,dind) SAH) SAH ;(6)

(aneurysmal subarachnoid hemorrhage, 17%~60% :SAH. ,asah , 22%~49% : Willis. :1927 Moniz ;(3) 2. ischemic neurological deficit,dind) SAH) SAH ;(6) ,, 2. : ;,, :(1), (delayed ;(2) ischemic neurological deficit,dind) ;(3) 2. :SAH ;(4) 5-10 10 HT -1-1 ;(5), 10 SAH ;(6) - - 27%~50%, ( cerebral vasospasm ) Glasgow (Glasgow Coma Scale,GCS), [1],, (aneurysmal

More information

はじめに 対象と方法 39: , 2017 SAH 183 WFNS

はじめに 対象と方法 39: , 2017 SAH 183 WFNS 39:107 原 著 39: 107 112, 2017 1 2 1 1 1 1 要旨 SAH 2010 1 2013 12 SAH 253 183 64 70 WFNS I III 72.7 Fisher CT 3 86.3 19.9 16.6 GR MD 73.2 73.1 80 WFNS Key words: subarachnoid hemorrhage, prognosis, rate of

More information

Progress Review. Mervyn D.I. Vergouwen, MD, PhD; Rob J. de Haan, PhD; Marinus Vermeulen, MD, PhD; Yvo B.W.E.M. Roos, MD, PhD

Progress Review. Mervyn D.I. Vergouwen, MD, PhD; Rob J. de Haan, PhD; Marinus Vermeulen, MD, PhD; Yvo B.W.E.M. Roos, MD, PhD Progress Review Effect of Statin Treatment on Vasospasm, Delayed Cerebral Ischemia, and Functional Outcome in Patients With Aneurysmal Subarachnoid Hemorrhage A Systematic Review and Meta-Analysis Update

More information

Neurointensive Care of Aneurysmal Subarachnoid Hemorrhage. Alejandro A. Rabinstein Department of Neurology Mayo Clinic, Rochester, USA

Neurointensive Care of Aneurysmal Subarachnoid Hemorrhage. Alejandro A. Rabinstein Department of Neurology Mayo Clinic, Rochester, USA Neurointensive Care of Aneurysmal Subarachnoid Hemorrhage Alejandro A. Rabinstein Department of Neurology Mayo Clinic, Rochester, USA The traditional view: asah is a bad disease Pre-hospital mortality

More information

SAH READMISSIONS TO NCCU

SAH READMISSIONS TO NCCU SAH READMISSIONS TO NCCU Are they preventable? João Amaral Rebecca Gorf Critical Care Outreach Team - NHNN 2015 Total admissions to NCCU =862 Total SAH admitted to NCCU= 104 (93e) (12.0%) Total SAH readmissions=

More information

Effect of early operation for ruptured aneurysms on prevention of delayed ischemic symptoms

Effect of early operation for ruptured aneurysms on prevention of delayed ischemic symptoms J Neurosurg 57:622-628, 1982 Effect of early operation for ruptured aneurysms on prevention of delayed ischemic symptoms MAMORU TANEDA, M.D. Department of Neurosurgery, Hanwa Memorial Hospital, Osaka,

More information

Assessment of Vasospasm and Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: Current concepts and Value of CT Perfusion and CT Angiography

Assessment of Vasospasm and Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: Current concepts and Value of CT Perfusion and CT Angiography Assessment of Vasospasm and Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: Current concepts and Value of CT Perfusion and CT Angiography Poster No.: C-2563 Congress: ECR 2012 Type: Educational

More information

Development of Nicardipine Prolonged-Release Implants After Clipping for Preventing Cerebral Vasospasm: From Laboratory to Clinical Trial

Development of Nicardipine Prolonged-Release Implants After Clipping for Preventing Cerebral Vasospasm: From Laboratory to Clinical Trial 178 The Open Conference Proceedings Journal, 2010, 1, 178-182 Open Access Development of Nicardipine Prolonged-Release Implants After Clipping for Preventing Cerebral Vasospasm: From Laboratory to Clinical

More information

Sub-arachnoid haemorrhage

Sub-arachnoid haemorrhage Sub-arachnoid haemorrhage Dr Mary Newton Consultant Anaesthetist The National Hospital for Neurology and Neurosurgery UCL Hospitals NHS Trust mary.newton@uclh.nhs.uk Kiev, Ukraine September 17 th 2009

More information

Intra-arterial nimodipine for the treatment of vasospasm due to aneurysmal subarachnoid hemorrhage

Intra-arterial nimodipine for the treatment of vasospasm due to aneurysmal subarachnoid hemorrhage Romanian Neurosurgery (2016) XXX 4: 461 466 461 DOI: 10.1515/romneu-2016-0074 Intra-arterial nimodipine for the treatment of vasospasm due to aneurysmal subarachnoid hemorrhage A. Chiriac, Georgiana Ion*,

More information

Treatment of Unruptured Vertebral Artery Dissecting Aneurysms

Treatment of Unruptured Vertebral Artery Dissecting Aneurysms 33 Treatment of Unruptured Vertebral Artery Dissecting Aneurysms Isao NAITO, M.D., Shin TAKATAMA, M.D., Naoko MIYAMOTO, M.D., Hidetoshi SHIMAGUCHI, M.D., and Tomoyuki IWAI, M.D. Department of Neurosurgery,

More information

Case report: Intra-procedural aneurysm rupture during endovascular treatment causing immediate, transient angiographic vasospasm Zoe Zhang, MD

Case report: Intra-procedural aneurysm rupture during endovascular treatment causing immediate, transient angiographic vasospasm Zoe Zhang, MD Case report: Intra-procedural aneurysm rupture during endovascular treatment causing immediate, transient angiographic vasospasm Zoe Zhang, MD, Farhan Siddiq, MD, Wondwossen G Tekle, MD, Ameer E Hassan,

More information

Effect of clot removal on cerebral vasospasm TETSUJI INAGAWA, M.D., MITSUO YAMAMOTO, M.D., AND KAZUKO KAMIYA, M.D.

Effect of clot removal on cerebral vasospasm TETSUJI INAGAWA, M.D., MITSUO YAMAMOTO, M.D., AND KAZUKO KAMIYA, M.D. J Neurosurg 72:224-230, 1990 Effect of clot removal on cerebral vasospasm TETSUJI INAGAWA, M.D., MITSUO YAMAMOTO, M.D., AND KAZUKO KAMIYA, M.D. Department of Neurosurgery, Shimane Prefectural Central Hospital,

More information

Definition พ.ญ.ส ธ ดา เย นจ นทร. Epidemiology. Definition 5/25/2016. Seizures after stroke Can we predict? Poststroke seizure

Definition พ.ญ.ส ธ ดา เย นจ นทร. Epidemiology. Definition 5/25/2016. Seizures after stroke Can we predict? Poststroke seizure Seizures after stroke Can we predict? พ.ญ.ส ธ ดา เย นจ นทร PMK Epilepsy Annual Meeting 2016 Definition Poststroke seizure : single or multiple convulsive episode(s) after stroke and thought to be related

More information

The learning curve associated with intracranial angioplasty and stenting: analysis from a single center

The learning curve associated with intracranial angioplasty and stenting: analysis from a single center Original Article Page 1 of 7 The learning curve associated with intracranial angioplasty and stenting: analysis from a single center Peiquan Zhou, Guang Zhang, Zhiyong Ji, Shancai Xu, Huaizhang Shi Department

More information

Letter to the Editor: test occlusion under monitoring of motor-evoked potentials for giant distal

Letter to the Editor: test occlusion under monitoring of motor-evoked potentials for giant distal Letter to the Editor: test occlusion under monitoring of motor-evoked potentials for giant distal anterior cerebral artery aneurysm Acta Neurochirurgica Kampei Shimizu, Shoichi Tani, Hirotoshi Imamura,

More information

Potential Roles for Statins in Critically Ill Patients

Potential Roles for Statins in Critically Ill Patients Potential Roles for Statins in Critically Ill Patients Kyle A. Weant, Pharm.D., and Aaron M. Cook, Pharm.D. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are the most commonly

More information

Posterior Cerebral Artery Aneurysms with Common Carotid Artery Occlusion: A Report of Two Cases

Posterior Cerebral Artery Aneurysms with Common Carotid Artery Occlusion: A Report of Two Cases Journal of Neuroendovascular Therapy 2017; 11: 371 375 Online March 3, 2017 DOI: 10.5797/jnet.cr.2016-0114 Posterior Cerebral Artery Aneurysms with Common Carotid Artery Occlusion: A Report of Two Cases

More information

Statins and endothelium function

Statins and endothelium function Statins and endothelium function Matthias Endres Berlin, Germany Klinik und Poliklinik für Neurologie Conflict of interest: research grant from AstraZeneca from prevention to acute therapy... Pleiotropic

More information

Clinical Review of 20 Cases of Terson s Syndrome

Clinical Review of 20 Cases of Terson s Syndrome 34 Clinical Review of 20 Cases of Terson s Syndrome Takashi SUGAWARA, M.D., Yoshio TAKASATO, M.D., Hiroyuki MASAOKA, M.D., Yoshihisa OHTA, M.D., Takanori HAYAKAWA, M.D., Hiroshi YATSUSHIGE, M.D., Shogo

More information

Current State of the Art

Current State of the Art SAH Current State of the Art Thomas C. Steineke, M.D., Ph.D. Director of Neurovascular Surgery NJ Neuroscience Institute JFK Medical Center Introduction Signs and symptoms of a problem What are aneurysms

More information

Clinical Analysis of Risk Factors Affecting Rebleeding in Patients with an Aneurysm. Gab Teug Kim, M.D.

Clinical Analysis of Risk Factors Affecting Rebleeding in Patients with an Aneurysm. Gab Teug Kim, M.D. / 119 = Abstract = Clinical Analysis of Risk Factors Affecting Rebleeding in Patients with an Aneurysm Gab Teug Kim, M.D. Department of Emergency Medicine, College of Medicine, Dankook University, Choenan,

More information

Regulation of lipid levels after ischemic stroke and an analysis of the associated factors in China

Regulation of lipid levels after ischemic stroke and an analysis of the associated factors in China Neurology Asia 2012; 17(4) : 273 279 ORIGINAL ARTICLES Regulation of lipid levels after ischemic stroke and an analysis of the associated factors in China Xin Wang, Ping Wang, Jun Li, Hai Feng Wang, Wei

More information

From the Cerebrovascular Imaging and Intervention Committee of the American Heart Association Cardiovascular Council

From the Cerebrovascular Imaging and Intervention Committee of the American Heart Association Cardiovascular Council American Society of Neuroradiology What Is a Stroke? From the Cerebrovascular Imaging and Intervention Committee of the American Heart Association Cardiovascular Council Randall T. Higashida, M.D., Chair

More information

Ischemia cerebrale dopo emorragia subaracnoidea Vasospasmo e altri nemici

Ischemia cerebrale dopo emorragia subaracnoidea Vasospasmo e altri nemici Ischemia cerebrale dopo emorragia subaracnoidea Vasospasmo e altri nemici Nino Stocchetti Milan University Neuroscience ICU Ospedale Policlinico IRCCS Milano stocchet@policlinico.mi.it Macdonald RL et

More information

Aneurysmal Subarachnoid Hemorrhage Presentation and Complications

Aneurysmal Subarachnoid Hemorrhage Presentation and Complications Aneurysmal Subarachnoid Hemorrhage Presentation and Complications Sherry H-Y. Chou MD MMSc FNCS Department of Critical Care Medicine, Neurology and Neurosurgery University of Pittsburgh School of Medicine

More information

Comparison of Five Major Recent Endovascular Treatment Trials

Comparison of Five Major Recent Endovascular Treatment Trials Comparison of Five Major Recent Endovascular Treatment Trials Sample size 500 # sites 70 (100 planned) 316 (500 planned) 196 (833 estimated) 206 (690 planned) 16 10 22 39 4 Treatment contrasts Baseline

More information

Endovascular Treatment for Acute Ischemic Stroke

Endovascular Treatment for Acute Ischemic Stroke ular Treatment for Acute Ischemic Stroke Vishal B. Jani MD Assistant Professor Interventional Neurology, Division of Department of Neurology. Creighton University/ CHI health Omaha NE Disclosure None 1

More information

Advances in the treatment of posterior cerebral circulation symptomatic disease

Advances in the treatment of posterior cerebral circulation symptomatic disease Advances in the treatment of posterior cerebral circulation symptomatic disease Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health

More information

UNIVERSA MEDICINA. Pleiotropic effects of statins in stroke prevention

UNIVERSA MEDICINA. Pleiotropic effects of statins in stroke prevention UNIVERSA MEDICINA May-August, 2009 Vol.28 - No.2 Pleiotropic effects of statins in stroke prevention Yenny* ABSTRACT Cardiovascular disease is the leading cause of death and disability, and contributes

More information

Redgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on

Redgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on 6. Imaging in TIA 6.1 What type of brain imaging should be used in suspected TIA? 6.2 Which patients with suspected TIA should be referred for urgent brain imaging? Evidence Tables IMAG1: After TIA/minor

More information

The Management and Treatment of Ruptured Abdominal Aortic Aneurysm (RAAA)

The Management and Treatment of Ruptured Abdominal Aortic Aneurysm (RAAA) The Management and Treatment of Ruptured Abdominal Aortic Aneurysm (RAAA) Disclosure Speaker name: Ren Wei, Li Zhui, Li Fenghe, Zhao Yu Department of Vascular Surgery, The First Affiliated Hospital of

More information

Michael Horowitz, MD Pittsburgh, PA

Michael Horowitz, MD Pittsburgh, PA Michael Horowitz, MD Pittsburgh, PA Introduction Cervical Artery Dissection occurs by a rupture within the arterial wall leading to an intra-mural Hematoma. A possible consequence is an acute occlusion

More information

What You Should Know About Cerebral Aneurysms

What You Should Know About Cerebral Aneurysms American Society of Neuroradiology American Society of Interventional & Therapeutic Neuroradiology What You Should Know About Cerebral Aneurysms From the Cerebrovascular Imaging and Intervention Committee

More information

Brain AVM with Accompanying Venous Aneurysm with Intracerebral and Intraventricular Hemorrhage

Brain AVM with Accompanying Venous Aneurysm with Intracerebral and Intraventricular Hemorrhage Cronicon OPEN ACCESS EC PAEDIATRICS Case Report Brain AVM with Accompanying Venous Aneurysm with Intracerebral and Intraventricular Hemorrhage Dimitrios Panagopoulos* Neurosurgical Department, University

More information

William Barr, M.D. January 28, 2017

William Barr, M.D. January 28, 2017 William Barr, M.D. January 28, 2017 Types of Stroke Ischemic Stroke Small vessel (20%) Large vessel (31%) Embolic (32%) Hemorrhagic Intracerebral Hemorrhage (10%) Subarachnoid Hemorrhage (7%) The Majority

More information

Summary of some of the landmark articles:

Summary of some of the landmark articles: Summary of some of the landmark articles: The significance of unruptured intracranial saccular aneurysms: Weibers et al Mayo clinic. 1987 1. 131 patients with 161 aneurysms were followed up at until death,

More information

Cerebral Vasospasm in Subarachnoid Hemorrhage Through Aneurysm Rupture - Clinical Considerations and Case Report

Cerebral Vasospasm in Subarachnoid Hemorrhage Through Aneurysm Rupture - Clinical Considerations and Case Report ARS Medica Tomitana - 2016; 4(22): 232-238 10.1515/arsm-2016-0040 Caraban B.M. 3, Romila Aurelia 2, Hangan L.T. 3, Lungu Mihaela 1 Cerebral Vasospasm in Subarachnoid Hemorrhage Through Aneurysm Rupture

More information

Medical Policy. MP Computed Tomography Perfusion Imaging of the Brain

Medical Policy. MP Computed Tomography Perfusion Imaging of the Brain Medical Policy MP 6.01.49 BCBSA Ref. Policy: 6.01.49 Last Review: 09/28/2017 Effective Date: 09/28/2017 Section: Radiology Related Policies 2.01.54 Endovascular Procedures for Intracranial Arterial Disease

More information

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no

More information

STATINS FOR PAD Long - term prognosis

STATINS FOR PAD Long - term prognosis STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest

More information

The Effect of Diagnostic Catheter Angiography on Outcomes of Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment

The Effect of Diagnostic Catheter Angiography on Outcomes of Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment The Effect of Diagnostic Catheter Angiography on Outcomes of Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Adnan I. Qureshi, MD 1, Muhammad A. Saleem, MD 1, Emrah Aytaç, MD

More information

Canadian Best Practice Recommendations for Stroke Care. (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management

Canadian Best Practice Recommendations for Stroke Care. (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management Canadian Best Practice Recommendations for Stroke Care (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management Reorganization of Recommendations 2008 2006 RECOMMENDATIONS: 2008 RECOMMENDATIONS:

More information

Aneurysmal subarachnoid hemorrhage (SAH)

Aneurysmal subarachnoid hemorrhage (SAH) LITERATURE REVIEW J Neurosurg 127:291 301, 2017 Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review

More information

Aneurysmal subarachnoid hemorrhage in the elderly:

Aneurysmal subarachnoid hemorrhage in the elderly: Aneurysmal subarachnoid hemorrhage in the elderly: Helsinki experience 1980-2008 Eljas Supponen, BM Student number: 013302559 Helsinki 04.05.2012 Thesis eljas.supponen@helsinki.fi Supervisors: Martin Lehecka,

More information

Management of Cerebral Aneurysms in Polycystic Kidney Disease. Dr H Stockley Consultant Neuroradiologist Greater Manchester Neuroscience Centre

Management of Cerebral Aneurysms in Polycystic Kidney Disease. Dr H Stockley Consultant Neuroradiologist Greater Manchester Neuroscience Centre Management of Cerebral Aneurysms in Polycystic Kidney Disease Dr H Stockley Consultant Neuroradiologist Greater Manchester Neuroscience Centre What is a cerebral aneurysm? Developmental degenerative arterial

More information

Mechanical thrombectomy in Plymouth. Will Adams. Will Adams

Mechanical thrombectomy in Plymouth. Will Adams. Will Adams Mechanical thrombectomy in Plymouth Will Adams Will Adams History Intra-arterial intervention 1995 (NINDS) iv tpa improved clinical outcome in patients treated within 3 hours of ictus but limited recanalisation

More information

Andrew Barreto, MD MS Associate Professor of Neurology Stroke Neurologist UTHealth. May 23, 2018

Andrew Barreto, MD MS Associate Professor of Neurology Stroke Neurologist UTHealth. May 23, 2018 Andrew Barreto, MD MS Associate Professor of Neurology Stroke Neurologist UTHealth May 23, 2018 Disclosure No personal financial relationships with any company. Presentation Outline Definitions, signs

More information

NIH Public Access Author Manuscript J Am Coll Radiol. Author manuscript; available in PMC 2013 June 24.

NIH Public Access Author Manuscript J Am Coll Radiol. Author manuscript; available in PMC 2013 June 24. NIH Public Access Author Manuscript Published in final edited form as: J Am Coll Radiol. 2010 January ; 7(1): 73 76. doi:10.1016/j.jacr.2009.06.015. Cerebral Aneurysms Janet C. Miller, DPhil, Joshua A.

More information

Cholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia

Cholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia Cholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies

More information

AEROMEDICAL DECISION MAKING IN CEREBRAL ANEURYSMS. Pooshan Navāthé Michael Drane Peter Clem David Fitzgerald

AEROMEDICAL DECISION MAKING IN CEREBRAL ANEURYSMS. Pooshan Navāthé Michael Drane Peter Clem David Fitzgerald AEROMEDICAL DECISION MAKING IN CEREBRAL ANEURYSMS Pooshan Navāthé Michael Drane Peter Clem David Fitzgerald Disclaimer I receive a salary from the Commonwealth of Australia. I have no financial relationships

More information

Moyamoya Syndrome with contra lateral DACA aneurysm: First Case report with review of literature

Moyamoya Syndrome with contra lateral DACA aneurysm: First Case report with review of literature Romanian Neurosurgery Volume XXXI Number 3 2017 July-September Article Moyamoya Syndrome with contra lateral DACA aneurysm: First Case report with review of literature Ashish Kumar Dwivedi, Pradeep Kumar,

More information

Impact of a Protocol for Acute Antifibrinolytic Therapy on Aneurysm Rebleeding After Subarachnoid Hemorrhage

Impact of a Protocol for Acute Antifibrinolytic Therapy on Aneurysm Rebleeding After Subarachnoid Hemorrhage Impact of a Protocol for Acute Antifibrinolytic Therapy on Aneurysm Rebleeding After Subarachnoid Hemorrhage Robert M. Starke, BA; Grace H. Kim, MD; Andres Fernandez, MD; Ricardo J. Komotar, MD; Zachary

More information

Neurosurgical decision making in structural lesions causing stroke. Dr Rakesh Ranjan MS, MCh, Dip NB (Neurosurgery)

Neurosurgical decision making in structural lesions causing stroke. Dr Rakesh Ranjan MS, MCh, Dip NB (Neurosurgery) Neurosurgical decision making in structural lesions causing stroke Dr Rakesh Ranjan MS, MCh, Dip NB (Neurosurgery) Subarachnoid Hemorrhage Every year, an estimated 30,000 people in the United States experience

More information

WHITE PAPER: A GUIDE TO UNDERSTANDING SUBARACHNOID HEMORRHAGE

WHITE PAPER: A GUIDE TO UNDERSTANDING SUBARACHNOID HEMORRHAGE WHITE PAPER: A GUIDE TO UNDERSTANDING SUBARACHNOID HEMORRHAGE Subarachnoid Hemorrhage is a serious, life-threatening type of hemorrhagic stroke caused by bleeding into the space surrounding the brain,

More information

Emergency Department Management of Acute Ischemic Stroke

Emergency Department Management of Acute Ischemic Stroke Emergency Department Management of Acute Ischemic Stroke R. Jason Thurman, MD Associate Professor of Emergency Medicine and Neurosurgery Associate Director, Vanderbilt Stroke Center Vanderbilt University,

More information

By Graham C. Wong, MD; and Christian Constance, MD. therapy in reducing long-term cardiovascular

By Graham C. Wong, MD; and Christian Constance, MD. therapy in reducing long-term cardiovascular Lipid-Lowering Therapy For Acute Coronary Syndromes There is a large amount of evidence that supports the early use of statins in the treatment of acute coronary syndromes. The anti-inflammatory, anti-thrombotic

More information

Blood Pressure Management in Acute Ischemic Stroke

Blood Pressure Management in Acute Ischemic Stroke Blood Pressure Management in Acute Ischemic Stroke Kimberly Clark, PharmD, BCCCP Clinical Pharmacy Specialist Critical Care, Greenville Health System Adjunct Assistant Professor, South Carolina College

More information

Index. average stress 146. see ACIS

Index. average stress 146. see ACIS Index ACIS (autonomous catheter insertion system) 156, 237 39, 241 49 acute stroke treatment 59, 69, 71 anatomical model 88 aneurismal clipping treatment 106, 110 aneurysm 2 3, 26, 47 50, 52 55, 67 68,

More information

lek Magdalena Puławska-Stalmach

lek Magdalena Puławska-Stalmach lek Magdalena Puławska-Stalmach tytuł pracy: Kliniczne i radiologiczne aspekty tętniaków wewnątrzczaszkowych a wybór metody leczenia Summary An aneurysm is a localized, abnormal distended lumen of the

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

Method Hannah Shotton

Method Hannah Shotton #asah Method Hannah Shotton 2 Introduction SAH Rupturing aneurysm Poor outlook Intervention Secure the aneurysm: clipping or coiling Recommended 48 hours Regional Specialist NSC Conservative management

More information

The rupture of an intracranial

The rupture of an intracranial Controversies in the management of aneurysmal subarachnoid hemorrhage* Neeraj S. Naval, MD; Robert D. Stevens, MD; Marek A. Mirski, MD, PhD; Anish Bhardwaj, MD, FCCM Background: The care of patients with

More information

Management of cerebral vasospasm

Management of cerebral vasospasm Neurosurg Rev DOI 10.1007/s10143-005-0013-5 REVIEW R. Loch Macdonald Management of cerebral vasospasm Received: 5 August 2005 / Revised: 28 October 2005 / Accepted: 4 November 2005 # Springer-Verlag 2005

More information

Surgical treatment and perioperative management of intracranial aneurysms in Chinese patients with ischemic cerebrovascular diseases: a case series

Surgical treatment and perioperative management of intracranial aneurysms in Chinese patients with ischemic cerebrovascular diseases: a case series Zheng and Wu BMC Neurology (2018) 18:142 https://doi.org/10.1186/s12883-018-1147-8 RESEARCH ARTICLE Open Access Surgical treatment and perioperative management of intracranial aneurysms in Chinese patients

More information

Recurring Extracranial Internal Carotid Artery Vasospasm Detected by Intravascular Ultrasound

Recurring Extracranial Internal Carotid Artery Vasospasm Detected by Intravascular Ultrasound CSE EPOT ecurring Extracranial Internal Carotid rtery Vasospasm Detected by Intravascular Ultrasound Tomohisa Dembo 1,2 and Norio Tanahashi 2 bstract 24-year-old woman presented with headache and left-sided

More information

Stroke Net Grand Round Webinar

Stroke Net Grand Round Webinar Stroke Net Grand Round Webinar Preconditioning the Brain for Stroke Prevention April 4, 2019 Sebastian Koch University of Miami Department of Neurology None Unique challenges in brain conditioning Review

More information

The Effect of Statin Therapy on Risk of Intracranial Hemorrhage

The Effect of Statin Therapy on Risk of Intracranial Hemorrhage The Effect of Statin Therapy on Risk of Intracranial Hemorrhage JENNIFER HANIFY, PHARM.D. PGY2 CRITICAL CARE RESIDENT UF HEALTH JACKSONVILLE JANUARY 23 RD 2016 Objectives Review benefits of statin therapy

More information

Intracranial Atherosclerosis in Asians

Intracranial Atherosclerosis in Asians Intracranial Atherosclerosis in Asians Anthony S. Kim, MD Assistant Clinical Professor of Neurology UCSF Neurovascular Service February 27, 2010 Disclosures Research Support National Institutes of Health

More information

Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease

Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon

More information

Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.

Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.

More information

Longitudinal anterior-to-posterior shift of collateral channels in patients with moyamoya disease: an implication for its hemorrhagic onset

Longitudinal anterior-to-posterior shift of collateral channels in patients with moyamoya disease: an implication for its hemorrhagic onset CLINICAL ARTICLE Longitudinal anterior-to-posterior shift of collateral channels in patients with moyamoya disease: an implication for its hemorrhagic onset Shusuke Yamamoto, MD, Satoshi Hori, MD, PhD,

More information

Imaging ischemic strokes: Correlating radiological findings with the pathophysiological evolution of an infarct

Imaging ischemic strokes: Correlating radiological findings with the pathophysiological evolution of an infarct Imaging ischemic strokes: Correlating radiological findings with the pathophysiological evolution of an infarct Jay Chyung,, PhD, HMS III Patient A: history 91 y.o. woman Acute onset R sided weakness and

More information

a. Ischemic stroke An acute focal infarction of the brain or retina (and does not include anterior ischemic optic neuropathy (AION)).

a. Ischemic stroke An acute focal infarction of the brain or retina (and does not include anterior ischemic optic neuropathy (AION)). 12.0 Outcomes 12.1 Definitions 12.1.1 Neurologic Outcome Events a. Ischemic stroke An acute focal infarction of the brain or retina (and does not include anterior ischemic optic neuropathy (AION)). Criteria:

More information

Perforator aneurysms of the posterior circulation. Spontaneous resolution of perforator aneurysms of the posterior circulation.

Perforator aneurysms of the posterior circulation. Spontaneous resolution of perforator aneurysms of the posterior circulation. J Neurosurg 121:1107 1111, 2014 AANS, 2014 Spontaneous resolution of perforator aneurysms of the posterior circulation Report of 3 cases Adrien Chavent, M.D., 1 Pierre-Henri Lefevre, M.D., 1 Pierre Thouant,

More information

Guideline scope Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management

Guideline scope Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management 0 0 NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management The Department of Health and Social Care in England

More information

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1. Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical

More information

Effects of Ezetimibe Added to Ongoing Statin Therapy on C-Reactive Protein Levels in Hypercholesterolemic Patients

Effects of Ezetimibe Added to Ongoing Statin Therapy on C-Reactive Protein Levels in Hypercholesterolemic Patients ORIGINAL ARTICLE DOI 10.4070/kcj.2011.41.5.253 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright 2011 The Korean Society of Cardiology Open Access Effects of Ezetimibe Added to Ongoing Statin Therapy

More information

Pre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease

Pre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease Pre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease Michael R. Jaff, D.O., F.A.C.P., F.A.C.C. Assistant Professor of Medicine Harvard Medical School Director, Vascular Medicine

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,

More information

Extent of subarachnoid hemorrhage and development of hydrocephalus

Extent of subarachnoid hemorrhage and development of hydrocephalus Clinical Science Extent of subarachnoid hemorrhage and development of hydrocephalus Mirsad Hodžić, Mirza Moranjkić, Zlatko Ercegović, Harun Brkić Department of neurosurgery, University Clinical Center

More information

Studying Aneurysm Devices in the Intracranial Neurovasculature

Studying Aneurysm Devices in the Intracranial Neurovasculature Studying Aneurysm Devices in the Intracranial Neurovasculature The benefits and risks of treating unruptured aneurysms depend on the anatomical location. One approach to studying devices to treat unruptured

More information

Dr. Shakir Husain MD, DM, FINR Consultant & Chief of Services Department of NeuroEndoVascular Therapy & Stroke. Program Director

Dr. Shakir Husain MD, DM, FINR Consultant & Chief of Services Department of NeuroEndoVascular Therapy & Stroke. Program Director EGAS MUNIZ FELLOWSHIP INTERVENTIONAL NEUROLOGY & STROKE Neurointervention is fast becoming an important subspecialty of neurosciences. There are many unexplored dimensions of these techniques, which may

More information

Sonuçlar: Yargı: Anahtar Kelimeler: INTRODUCTION MATERIAL AND METHODS

Sonuçlar: Yargı: Anahtar Kelimeler: INTRODUCTION MATERIAL AND METHODS Journal of Neurological Sciences [Turkish] 31:(4)# 42; 718-725, 2014 http://www.jns.dergisi.org/text.php3?id=822 Research Article Comparison of Nimodipine Administration Routes in Cerebral Vasospasm After

More information

Convulsion During Intra-arterial Infusion of Fasudil Hydrochloride for the Treatment of Cerebral Vasospasm Following Subarachnoid Hemorrhage

Convulsion During Intra-arterial Infusion of Fasudil Hydrochloride for the Treatment of Cerebral Vasospasm Following Subarachnoid Hemorrhage Neurol Med Chir (Tokyo) 50, 7 12, 2010 Convulsion During Intra-arterial Infusion of Fasudil Hydrochloride for the Treatment of Cerebral Vasospasm Following Subarachnoid Hemorrhage Yukiko ENOMOTO, ShinichiYOSHIMURA,

More information

Advances in Neuro-Endovascular Care for Acute Stroke

Advances in Neuro-Endovascular Care for Acute Stroke Advances in Neuro-Endovascular Care for Acute Stroke Ciarán J. Powers, MD, PhD, FAANS Associate Professor Program Director Department of Neurological Surgery Surgical Director Comprehensive Stroke Center

More information

Quantitative Analysis of Hemorrhage Volume for Predicting Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Quantitative Analysis of Hemorrhage Volume for Predicting Delayed Cerebral Ischemia After Subarachnoid Hemorrhage Quantitative Analysis of Hemorrhage Volume for Predicting Delayed Cerebral Ischemia After Subarachnoid Hemorrhage Sang-Bae Ko, MD, PhD; H. Alex Choi, MD; Amanda Mary Carpenter, BA; Raimund Helbok, MD;

More information

Co chce/čeká neurochirug od anesteziologa během karotické endarterektomie?

Co chce/čeká neurochirug od anesteziologa během karotické endarterektomie? XXV. kongres České společnosti anesteziologie, resuscitace a intenzivní medicíny, Praha 3.-5.10. 2018 Co chce/čeká neurochirug od anesteziologa během karotické endarterektomie? Hejčl A., Orlický M., Sameš

More information

Noninvasive Methods of Neurovisualization in the Diagnostics of Secondary Ischemia at Nontraumatic Intracranial Hemorrhages

Noninvasive Methods of Neurovisualization in the Diagnostics of Secondary Ischemia at Nontraumatic Intracranial Hemorrhages American Journal of Medicine and Medical Sciences 2019, 9(1): 2-4 DOI: 10.592/j.ajmms.20190901.05 Noninvasive Methods of Neurovisualization in the Diagnostics of Secondary Ischemia at Nontraumatic Intracranial

More information

TEMPORARY occlusion of the cerebral vasculature

TEMPORARY occlusion of the cerebral vasculature PERIOPERATIVE MEDICINE Anesthesiology 2010; 112:86 101 Copyright 2009, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins No Association between Intraoperative Hypothermia or

More information

New Frontiers in Intracerebral Hemorrhage

New Frontiers in Intracerebral Hemorrhage New Frontiers in Intracerebral Hemorrhage Ryan Hakimi, DO, MS Director, Neuro ICU Director, Inpatient Neurology Services Greenville Health System Clinical Associate Professor Department of Medicine (Neurology)

More information

Recombinant Factor VIIa for Intracerebral Hemorrhage

Recombinant Factor VIIa for Intracerebral Hemorrhage Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage

More information

Stroke Update. Lacunar 19% Thromboembolic 6% SAH 13% ICH 13% Unknown 32% Hemorrhagic 26% Ischemic 71% Other 3% Cardioembolic 14%

Stroke Update. Lacunar 19% Thromboembolic 6% SAH 13% ICH 13% Unknown 32% Hemorrhagic 26% Ischemic 71% Other 3% Cardioembolic 14% Stroke Update Michel Torbey, MD, MPH, FAHA, FNCS Medical Director, Neurovascular Stroke Center Professor Department of Neurology and Neurosurgery The Ohio State University Wexner Medical Center Objectives

More information

NEWS ON ISCHEMIC HEART DISEASE AT THE ESC 2018 CONGRESS MARIO MARZILLI, MD, PhD

NEWS ON ISCHEMIC HEART DISEASE AT THE ESC 2018 CONGRESS MARIO MARZILLI, MD, PhD NEWS ON ISCHEMIC HEART DISEASE AT THE ESC 2018 CONGRESS MARIO MARZILLI, MD, PhD Author affiliations: Cardiovascular Medicine Division, Pisa University Medical School, Pisa, Italy Address for correspondence:

More information

Endovascular Treatment of Symptomatic Vertebral Artery Dissecting Aneurysms

Endovascular Treatment of Symptomatic Vertebral Artery Dissecting Aneurysms Journal of Cerebrovascular and Endovascular Neurosurgery pissn 2234-8565, eissn 2287-3139, http://dx.doi.org/10.7461/jcen.2016.18.3.201 Original Article Endovascular Treatment of Symptomatic Vertebral

More information

Female, years or younger BMI of 30 or less at time of Diabetes diagnosis Prefer no family history of diabetes Took Lipitor consistently for at

Female, years or younger BMI of 30 or less at time of Diabetes diagnosis Prefer no family history of diabetes Took Lipitor consistently for at Female, 51-70 years or younger BMI of 30 or less at time of Diabetes diagnosis Prefer no family history of diabetes Took Lipitor consistently for at least two months prior to diagnosis or within six months

More information